Tetra Therapeutics

Tetra Therapeutics is a biotechnology company founded in 2010 and headquartered in the United States. The company's slogan "Restoring Clarity of Thought" aligns with its core mission of developing medicines for various neurological disorders including Alzheimer's Disease, Fragile X syndrome, Traumatic Brain Injury, major depression, and schizophrenia. Tetra Therapeutics is currently in the clinical stage, with a focus on designing drugs that target PDE4B and PDE4D, offering a new mechanism to address memory loss and cognitive impairment. The company's most promising drug for Alzheimer's Disease, BPN-14770, is part of a partnership with the NIH Blueprint Therapeutics program. The recent Series A investment of $5.00M on 29 November 2016 was led by Grand Angels and Apjohn Ventures. Tetra's innovative approach and promising drug pipeline make it an attractive prospect for investors seeking opportunities in the biotechnology sector. The company's focus on addressing neuroinflammation, progressive multiple sclerosis (MS), and chronic traumatic encephalopathy (CTE) positions it as a potential leader in the field of neurological therapeutics.